Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Flexible iris-fixated phakic lens in the treatment of moderate to high myopia: refractive, visual and safety results after 5 years

Search Title by author or title

Session Details

Session Title: Phakic IOLs

Session Date/Time: Monday 09/10/2017 | 08:30-10:20

Paper Time: 08:36

Venue: Meeting Center Room I

First Author: : J.Costa PORTUGAL

Co Author(s): :    T. Monteiro   N. Franqueira   F. Faria-Correia   F. Vaz           

Abstract Details


The surgical treatment of moderate to high myopia may involve several strategies, being the implantation of a phakic intraocular lens (IOL) the preferred option in younger patients. The Artiflex® is a model of phakic, flexible, iris-fixated IOL. The aim of this study was to analyze the efficacy and safety of Artiflex® lens implant (Ophtec BV, Groningen, Netherlands) for refractive correction of moderate to high myopia.


Ophthalmology Department of Hospital de Braga, Braga, Portugal


We analyzed data from 142 eyes of 68 patients undergoing Artiflex® lens implant for high myopia correction, between January 2010 and July 2016. The minimum follow-up time varied between 12 and 60 months and the parameters analyzed were: under corrected visual acuity (UCVA) and best-corrected visual acuity (BCVA); spherical equivalent; subjective refraction spherical and cylindrical; and endothelial cell count. The indexes for efficacy and safety were also calculated.


At 12 months, we obtained a significant improvement in BCVA, from 0.80±0.19 to 0.92±0.16. 53% of eyes achieved gains of 1 or more lines of BCVA, while 6.9% have lost 1 or more lines of BCVA; spherical equivalent decreased from -9.47D±3.82 to -0.21D±0.47 at 12 months and -1.04D±0.64 at 60 months. At 12 months, 76% of patients achieved a spherical equivalent between ±0.50D and 96% within ±1.0D. We obtained an average loss of endothelial cells of -1.72% at 12 months, -4.31% at 24 months, -5.87% at 36 months, -9.47% at 60 months, equivalent to an average annual loss of -2.36%.


The phakic intraocular lens Artiflex® is an effective, safe and stable treatment of moderate to high myopia. A careful annual follow-up is mandatory to monitor the density of endothelial cells and other associated rare complications.

Financial Disclosure:


Back to previous